ClinicalTrials.gg
Enrolling by invitationNCT06597188PROMIS-BAVUpdated Sep 16, 2025

TAVR vs. SAVR Study of VitaFlow Liberty® for Severe BAV Stenosis

An interventional study of VitaFlow Liberty and Commercially available surgical bioprosthetic valve in Aortic Stenosis and Bicuspid Aortic Valve (BAV), sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Shanghai MicroPort CardioFlow Medtech Co., Ltd. (part of MicroPort Scientific Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Aortic Valve Stenosis with a site in China — 43 open to participants now, 51 under way, 3 of them phase 3. Aortic Valve Stenosis · China.

Planned enrollment
6th of 47
452 · median 120
Started
2025
with 10 others
No phase
37 of 69
20 open now
Primary completion
2028-09
later than 43 of 50 live
Registered
43rd of 69
by date
Lead sponsor
6 of 69
Shanghai MicroPort CardioFlow Medtech Co., Ltd.

Among the 69 studies in Aortic Valve Stenosis with a site in China, this one is the 6th largest by planned enrollment of the 47 interventional ones that give a count, is one of 11 that started in 2025, is one of 37 with no phase, reaches primary completion later than 43 of the 50 other live ones, and was the 43rd registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

43 of the 69 studies in Aortic Valve Stenosis with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Aortic Valve Stenosis with a site in China, or all of them as a file.
02

Study summary

To evaluate the safety and effectiveness of the Transcatheter aortic valve and retrievable delivery system (VitaFlow Liberty®) for the treatment of severe bicuspid aortic valve (BAV) stenosis.

Read the detailed description

Transcatheter aortic valve replacement (TAVR) has emerged as the first-line treatment for symptomatic severe AS currently, while TAVR for bicuspid aortic valve (BAV) stenosis has not been well demonstrated in randomized controlled trials, thus more randomized controlled studies of TAVR vs. SAVR are still needed to provide strong evidence that TAVR treatment for patients with BAV stenosis has good safety and effectiveness.

This study is a prospective, international multicenter, randomized controlled, non-inferiority clinical study, in which the study device (VitaFlow Liberty®) for TAVR is to be demonstrated as non-inferior to the control device (a commercially available surgical bioprosthetic valve) for SAVR in terms of the incidence of composite endpoint events (all-cause mortality, all strokes and re-hospitalizations) at 12 months postoperatively.

In this study, 452 eligible subjects will be randomly assigned to the study group (n=226) or the control group (n=226) in a 1:1 ratio. The subjects in study group will be treated with the TAVR surgery using the study device (VitaFlow Liberty®) , while the subjects in control group will be treated with the SAVR surgery using the control device (a commercially available surgical bioprosthetic valve), and clinical follow-ups will be performed at discharge (or 7 days after surgery), 30 days, 6 months, 12 months, and 2, 3, 4, 5 years after surgery, respectively.

03

Conditions studied

  • Aortic Stenosis
  • Bicuspid Aortic Valve (BAV)

Keywords

  • Aortic stenosis
  • Bicuspid Aortic Valve (BAV)
  • TAVR
  • SAVR
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject aged ≤ 75 years;
  2. With symptomatic severe bicuspid aortic stenosis, defined as: peak flow velocity ≥ 4.0m/s, or mean trans-aortic pressure gradient ≥ 40mmHg, or aortic orifice area (AVA) ≤ 1.0cm2 (or AVA index ≤ 0.6cm2/m2) confirmed by echocardiography;
  3. (NYHA) cardiac function classification ≥ Class II;
  4. With an intermediate or low risk of surgical procedures (STS score ≤8%) assessed by the local heart team;
  5. Voluntarily participate in this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or resistance to study device and control device components such as nitinol or contrast media;
  2. Known or allergy to anticoagulant or antiplatelet medications and inability to tolerate the anticoagulant or antiplatelet therapy;
  3. Known presence of active infective endocarditis or other active infection;
  4. Known presence of severe vascular disease that precludes safe implantation of the prosthetic valve;
  5. Ascending aorta width ≥50mm;
  6. Previous prosthetic valve implantation (mechanical or bioprosthetic) in any heart place;
  7. The aortic root anatomy not suitable for transcatheter aortic valve implantation confirmed by preoperative imaging (including aortic root calcification that influence the sufficient dilatation of the rposthetic valve);
  8. Intracardiac mass, left ventricular or left atrial thrombus, vegetations confirmed by preoperative echocardiography;
  9. Acute myocardial infarction (defined as Q-wave MI or non-Q-wave MI) within 30 days prior to surgery;
  10. Invasive therapeutic cardiac surgery within 30 days prior to surgery (except for temporary pacemaker or implantable cardioverter-defibrillator implantation);
  11. Clinically diagnosed stroke or within 3 months prior to surgery;
  12. Gastrointestinal bleeding requiring hospitalization or transfusion therapy or other bleeding or coagulation disorders within 3 months prior to surgery, which preclude the required antiplatelet therapy in the study;
  13. Comorbid with severe native coronary artery lesions that require revascularization therapy;
  14. Comorbid with severe mitral or tricuspid regurgitation;
  15. Comorbid with cardiogenic shock or hemodynamic instability requiring support from positive inotropic agents or mechanical ventilation or mechanical cardiac assistance;
  16. Comorbid with severe left ventricular dysfunction (defined as LVEF \<20%);
  17. Comorbid with end-stage renal diseases requiring chronic dialysis;
  18. Comorbid with blood dyscrasias defined as leukopenia (white blood cell count \< 3×109/L), thrombocytopenia ( count \< 50×109/L), history of bleeding diathesis or coagulopathy, or hypercoagulable states;
  19. Subjects corresponding to the criteria of a vulnerable population (including patients who are unable to fully understand all aspects of the study, patients lacking capacity in the procedure and patients with dementia and cognitive impairment);
  20. Female subjects known to be pregnant or lactating;
  21. is less than 12 months as assessed by the investigator;
  22. Subject is participating in or planning to participate in other drug or device clinical studies within 12 months postoperatively;
  23. Any other condition that, at the discretion of investigator or heart team, may preclude the subject's safe participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
452 participants (estimated)

Study arms

  • Experimental
    TAVR group

    TAVR with the study device will be performed in the TAVR group

    Device: VitaFlow Liberty

  • Active comparator
    SAVR group

    SAVR with a commercially available surgical bioprosthetic valve will be performed in the control group

    Device: Commercially available surgical bioprosthetic valve

Interventions

  • DeviceVitaFlow Liberty

    All subjects randomized to the TAVR group will receive transcatheter aortic valve replacement (TAVR) with the study device of VitaFlow Liberty

  • DeviceCommercially available surgical bioprosthetic valve

    All subjects randomized to the SAVR group will receive surgical aortic valve replacement (SAVR) with the control device of a commercially available surgical bioprosthetic valve.

06

What researchers measure

Primary outcomes

  1. Incidence of composite endpoint events (all-cause mortality, all strokes, and re-hospitalizations [surgery, valve or heart failure related re-hospitalizations])

    The composite endpoint event at 12 months postoperatively refers to all-cause mortality, all strokes, and re-hospitalizations related to procedure, valve or heart failure that occur within 12 months postoperatively.

    Time frame: 12 months postoperatively

Secondary outcomes

  1. Device success rate

    Device success is defined as meeting all the following criteria: 1. Correct positioning of a single prosthetic heart valve into the proper anatomical location; 2. Successful access, delivery of the device, and retrieval of the delivery system; 3. Freedom from mortality; 4. Freedom from surgery or intervention related to the devicea or to a major vascular or access-related or cardiac structural complication; 5. Intended performance of the valvec (mean gradient \<20mmHg, peak velocity \<3 m/s, Doppler velocity index ≥ 0.25, and less than moderate aortic regurgitation).

    Time frame: 30 days postoperatively

  2. Prosthetic valve performance evaluation

    The prosthetic valve performance will be evaluated independently by the corelab based on the echocardiography.

    Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively

  3. New York Heart Association grading assessment of cardiac function

    New York Heart Association (NYHA) grading system includes four gradings with higher grading means severer outcome.

    Time frame: Discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively

  4. Quality of life assessment (Kansas City Cardiomyopathy Questionnaire score)

    Kansas City Cardiomyopathy Questionnaire (KCCQ) score is ranged from 0 to 100 with higher score means better quality of life.

    Time frame: 30 days, 6 months, 12 months postoperatively

  5. All-cause mortality

    According to the VARC3 criteria, all-cause mortality includes cardiovascular mortality and non-cardiovascular mortality.

    Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively

  6. Incidence of all strokes

    According to the VARC3 criteria, all strokes include ischemic strokes (including TIAs), hemorrhagic strokes, and unspecified strokes, as well as disabling and non-disabling strokes.

    Time frame: 30 days, 6 months, 12 months, 2 to 5 years postoperatively

  7. Incidence of myocardial infarction

    Myocardial infarction in this study is defined according to the VARC3 criteria.

    Time frame: Discharge, 30 days, 6 months, 12 months, 2-5 years postoperatively

  8. Incidence of major adverse cardiovascular and cerebrovascular events (MACCE)

    MACCE includes all-cause mortality, myocardial infarction, all strokes, and reoperation due to valvular dysfunction, with each event defined according to the VARC3 criteria.

    Time frame: 30 days, 6 months, 12 months postoperatively

  9. Incidence of life-threatening or disabling major bleeding

    Life-threatening or disabling major bleeding is defined as types 3 and 4 bleeding according to the VARC3 criteria.

    Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively

  10. Incidence of acute kidney injury (AKI)

    According to the VARC3 criteria, AKI is defined as stages 2-4 acute kidney injury.

    Time frame: Discharge, 30 days postoperatively

  11. Incidence of conduction disturbance and arrhythmias

    Conduction disturbance and arrhythmias are defined according to the VARC3 criteria.

    Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively

  12. Incidence of permanent pacemaker implantation

    Defined as the percentage of subjects with newly permanent pacemaker implantation occurring after surgery among all subjects enrolled in each group.

    Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively

  13. Incidence of serious vascular complications

    Serious vascular complications are defined according to the VARC3 criteria.

    Time frame: 30 days, 6 months, 12 months postoperatively

  14. Incidence of other TAVR-related complications

    Other TAVR-related complications include: conversion to surgery, unplanned cardiopulmonary mechanical assistance, coronary artery occlusion requiring intervention, ventricular septal perforation, mitral valve damage or dysfunction, cardiac tamponade, endocarditis, valvular thrombosis, valvular dyslocation (displacement, embolization, false release), and reoperation due to valve dysfunction (including surgical or interventional therapy).

    Time frame: Immediately, 30 days, 6 months, 12 months, 2-5 years postoperatively

  15. Incidence of Bioprosthetic valve dysfunction (BVD)

    BVD includes structural valve deterioration (SVD), moderate and severe prosthesis-patient mismatch (PPM), moderate and severe paravalvular leak (PVL), thrombosis or endocarditis.

    Time frame: 12 months, 2-5 years postoperatively

  16. Moderate to severe structural valvular deterioration (HVD)

    Moderate HVD is defined as an increase in mean transvalvular gradient ≥ 10mmHg resulting in mean gradient ≥ 20mmHgc with concomitant decrease in EOA ≥ 0.3cm2 or ≥ 25% and/or decrease in Doppler velocity index ≥ 0.1 or ≥ 20% compared with echocardiographic assessment performed 1-3 months post-procedure, OR new occurrence or increase of ≥ 1 graded of intraprosthetic AR resulting in ≥ moderate AR. Severe HVD is defined as an increase in mean transvalvular gradient ≥ 20mmHg resulting in mean gradient ≥ 30mmHgc with concomitant decrease in EOA ≥ 0.6cm2 or ≥50% and/or decrease in Doppler velocity index ≥0.2 or ≥40% compared with echocardiographic assessment performed 1-3 months post-procedure, OR new occurrence, or increase of ≥ 2 grades,d of intraprosthetic AR resulting in severe AR

    Time frame: 12 months, 2-5 years postoperatively

  17. Bioprosthetic valve dysfunction (BVF)

    BVF is a composite endpoint, including severe HVD, aortic valve reintervention, and valve-related mortality (investigator assessment).

    Time frame: 12 months, 2-5 years postoperatively

  18. Re-hospitalization related to procedure, valve or heart failure

    Re-hospitalization related to procedure, valve or heart failure is defined according to the VARC3 criteria.

    Time frame: 30 days, 6 months, 12 months, 2-5 years postoperatively

  19. Incidence of adverse events (AEs)

    An AE is an untoward medical occurrence during the course of the clinical study, regardless of whether or not related to the study device

    Time frame: throughout the clinical study period

  20. Incidence of serious adverse events (SAEs)

    Serious adverse event (SAE) refers to any adverse event that occurs during the clinical study of a medical device that results in any of the following: 1. Leads to death, or 2. Leads to serious deterioration of the health conditions, including: Fatal disease or injury Permanent defect in the physical structure or physical function Requiring hospitalization or prolongation of hospital stay Any event which requires medical or surgical intervention to prevent persistent disability/incapacity 3. Leads to fetal distress, fetal death or congenital abnormality or congenital defect, etc. Note: Planned hospitalizations due to pre-existing disease conditions, or events that do not result in significant deterioration in health status due to procedures required by the clinical study program are not considered SAEs.

    Time frame: throughout the clinical study period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's planned 36 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Sep 19, 2024
StartActual
Sep 8, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2032
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06597188
Collaborators
West China Hospital, The First Affiliated Hospital of Anhui Medical University, Zhejiang University, Qilu Hospital of Shandong University, People's Hospital of Xinjiang Uygur Autonomous Region, Provincial Hospital of fuzhou University, Yan'an Affiliated Hospital of Kunming Medical University
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 8, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2032 (estimated)
Last update
Sep 16, 2025

Study contacts

Mao Chen, Professor
principal investigator · West China Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion